Medicure
MPH.V- 1M
- +53.7%
Medicure in brief
Medicure is a listed company in the Pharmaceutical industry, based in Canada. Its market value was $32 M on 31 October 2026, which makes it the 22,796th largest listed company in the world and the 1,001st largest in Canada on this site. In the year to December 2024 it had sales of $16 M and a net loss of $1 M. Its largest business segments by sales in 2025 were Retail and Mail Order Pharmacy (70%) and Marketing and Distribution of Commercial Products (30%). Its shares trade under the symbol MPH.V (TSX Venture).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Market cap history
World rank over time
Rank in Canada: #582 (Jan 2020) · #724 (Jan 2021) · #1,725 (Jan 2022) · #1,388 (Dec 2022) · #1,224 (Jul 2023) · #1,220 (Jan 2024) · #1,177 (Sep 2026) · #1,001 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 2.0×
- Price / book
- 2.2×
- Free cash flow yield
- —
- Net margin (TTM)
- -4.8%
- Operating margin
- —
- Return on equity
- -5.3%
- Liabilities / assets
- 30.0%
- Net debt
- $42M
- Revenue growth
- -0.4%
- R&D / revenue
- 14.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $16M | -0.4% | — | $-1M | -4.8% |
| Dec 2023 | $16M | -9.3% | — | $-1M | -4.2% |
| Dec 2022 | $18M | +2.2% | — | $1M | 5.9% |
| Dec 2021 | $17M | +100.2% | — | $-1M | -3.3% |
| Dec 2020 | $9M | -43.0% | — | $-5M | -59.0% |
| Dec 2019 | $15M | -32.4% | — | $-15M | -98.1% |
| Dec 2018 | $22M | +7.5% | $-1M | $3M | 13.5% |
| Dec 2017 | $21M | — | $3M | $33M | 160.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2024 | $1M | — | — | $-0.07 | — |
| Dec 2023 | $2M | — | — | $-0.07 | — |
| Dec 2022 | $1M | — | — | $0.10 | — |
| Dec 2021 | $3M | — | — | $-0.06 | — |
| Dec 2020 | $-2M | — | — | $-0.48 | — |
| Dec 2019 | $-11M | — | — | $-0.99 | — |
| Dec 2018 | $1M | — | — | $0.19 | — |
| Dec 2017 | $17M | — | — | $1.84 | — |
SEC filings
- Aug 19, 20266-KReport of foreign issuer
- Aug 19, 20266-KReport of foreign issuer
- May 21, 20266-KReport of foreign issuer
- May 21, 20266-KReport of foreign issuer
- May 21, 20266-KReport of foreign issuer
- Apr 24, 20266-KReport of foreign issuer
- Apr 24, 202620-FAnnual report (foreign issuer) · period to Dec 2025
- Apr 23, 20266-KReport of foreign issuer
- Nov 19, 20256-KReport of foreign issuer
- Nov 19, 20256-KReport of foreign issuer
- Nov 14, 20256-KReport of foreign issuer
- Aug 21, 20256-KReport of foreign issuer
Official filings of Medicure with the US Securities and Exchange Commission.
Annual results
- Revenue
- $16 M
- Operating income
- —
- Net income
- $-1 M
For year ending December-2024 · source: SEC filing
Balance sheet
- Total assets
- $21 M
- Total liabilities
- $6 M
- Total equity
- $14 M
As of December-2024
Medicure scorecard#
Passes 4 of the 14 checks that could be worked out: strongest in valuation (2 of 4), weakest in profitability (0 of 3). Fiscal year 2024; market cap of Oct 31, 2026.
Valuation2 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median2.2×Price to book 2.2× against Pharmaceutical's median of 3.2×.
- ✓Price to sales below its peers' median2.0×Price to sales 2.0× against Pharmaceutical's median of 3.5×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✗Revenue grew in the newest year-0.4%Revenue down 0.4% in fiscal 2024.
- ✗Revenue up more than 5% a year over three years-2.6%-2.6% a year over the three years to fiscal 2024.
- ✗Faster growth over three years than its peers' median-2.6%-2.6% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✗Earnings per share grew in the newest year-0.07 vs -0.07Diluted EPS -0.07 in fiscal 2024 against -0.07 the year before (report's currency).
- ✓Net income higher than five years earlier-$1 M-$1 M in fiscal 2024 against -$15 M in 2019.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2024.
Profitability0 of 3
- ✗Profitable in the newest year-$1 MNet income -$1 M in fiscal 2024.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2024.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-5.2%-5.2% in fiscal 2024.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 1
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2024.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2024#
Worked out from Medicure's statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2024 | Median of peers |
|---|---|---|---|
| Net margin | -4.8% | -1.5% | |
| Return on equity | -5.2% | -0.9% | |
| Revenue growth, 3 years a year | -2.7% | 2.5% | |
| Revenue growth | -0.4% | 7.3% |
4of 7on the Piotroski tests of financial strength
- Revenue fell 0.4% against the year before.
- Net loss of $1 million.
Medicure: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in CAD millions; per-share figures in CAD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 22+1.0%100% | 22−5.9%100% | 23+6.1%100% | 22+87.3%100% | 12−42.4%100% | 20−30.7%100% | 29r29+7.3%100% | 27r27−7.4%100% | 29+32.7%100% | 22—100% | |
| Cost of revenue | 8.8+14.4%40.3% | 7.7+10.2%35.5% | 7.0−22.6%30.3% | 9.0+39.4%41.5% | 6.5−10.9%55.8% | 7.3+75.1%36.0% | 4.2r4.2+19.8%14.3% | 3.5r3.5−6.9%12.8% | 3.7+64.7%12.7% | 2.3—10.2% | |
| Gross profit | 13−6.4%59.7% | 14−13.0%64.5% | 16+26.5%69.7% | 13+148%58.5% | 5.1−60.2%44.2% | 13−48.3%64.0% | 25r25+5.4%85.7% | 24r24−7.5%87.2% | 26+29.1%87.3% | 20—89.8% | |
| Research and development | 3.1+28.1%14.1% | 2.4−12.6%11.1% | 2.8+53.3%11.9% | 1.8−45.6%8.3% | 3.3−24.1%28.4% | 4.3−34.9%21.6% | 6.7r6.7+29.8%23.0% | 5.1r5.1+41.8%19.0% | 3.6−25.4%12.4% | 4.9—22.0% | |
| Selling, general and administrative | — | — | — | — | — | — | 20+31.2%67.0% | 15−3.6%54.8% | 15+50.6%52.6% | 10—46.4% | |
| General and administrative | 1.0+73.6%4.4% | 0.6−59.7%2.6% | 1.4−1.4%6.0% | 1.4+251%6.4% | 0.4−51.5%3.4% | 0.8−45.4%4.1% | 1.5r1.5−12.8%5.2% | 1.7r1.7+13.0%6.4% | 1.5+61.0%5.2% | 0.9—4.3% | |
| Total costs and expenses | 16+6.6%72.2% | 15−0.3%68.4% | 15+0.5%64.5% | 15+11.8%68.1% | 13−37.4%114% | 21−19.2%105% | 26r26+30.8%89.9% | 20r20+5.1%73.8% | 19+26.1%65.0% | 15—68.4% | |
| Operating income | — | — | — | — | — | — | −1.2−134%−4.2% | 3.7−44.1%13.5% | 6.5+38.4%22.3% | 4.7—21.4% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | 0.8−66.2%3.1% | 2.5−39.9%8.5% | 4.1—18.7% | |
| Income before tax | −0.8—−3.6% | −0.9−165%−4.1% | 1.4—6.0% | −0.8—−3.5% | −6.8—−59.0% | −20−507%−97.4% | 4.8r4.8+97.9%16.6% | 2.4r2.4−35.8%9.0% | 3.8+194%12.9% | 1.3—5.8% | |
| Income tax | −0.3—−1.2% | −0.0—−0.1% | −0.0r0.0−163%−0.1% | 0.0r−0.0—0.1% | 0−100%0.0% | 0.1−83.8%0.7% | 0.9r0.9—3.1% | −9.1r9.1−5423%−33.4% | 0.2r−0.2−55.1%0.6% | 0.4—1.7% | |
| Income from continuing operations | −1.0—−4.7% | −0.9−168%−4.3% | 1.4—5.9% | −0.7—−3.3% | −6.8—−59.0% | −20−604%−98.1% | 3.9r3.9−65.9%13.5% | 11r11+217%42.4% | 3.6+117%12.4% | 1.7—7.6% | |
| Income from discontinued operations | — | — | — | — | — | — | 3.9r0−87.7%13.5% | 32r32+36.7%118% | 23—79.7% | — | |
| Net income including minority interests | −1.0—−4.7% | −0.9−168%−4.3% | 1.4—5.9% | −0.7—−3.3% | −6.8—−59.0% | −20−604%−98.1% | 3.9r3.9−91.0%13.5% | 43r43+60.9%160% | 27+1517%92.1% | 1.7—7.6% | |
| Earnings per share, basic | -0.10—— | -0.09−169%— | 0.13—— | -0.07—— | -0.64—— | -1.32−628%— | 0.25−91.0%— | 2.78+54.4%— | 1.80+1400%— | 0.12—— | |
| Earnings per share, diluted | -0.10—— | -0.09−169%— | 0.13—— | -0.07—— | -0.64—— | -1.32−650%— | 0.24−90.0%— | 2.39+53.2%— | 1.56+1318%— | 0.11—— | |
| Shares, weighted average (basic) | 100.0%— | 10+1.8%— | 100.0%— | 100.0%— | 10r11−31.7%— | 15−5.0%— | 16+1.0%— | 16+4.2%— | 15+11.4%— | 13—— | |
| Shares, weighted average (diluted) | 100.0%— | 100.0%— | 10+1.8%— | 100.0%— | 10r11−31.7%— | 15−9.4%— | 17−8.7%— | 18+4.7%— | 17+9.8%— | 16—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 7.2+12.9%24.2% | 6.4+31.1%22.7% | 4.9+31.5%16.2% | 3.7+36.0%13.0% | 2.7−79.1%8.0% | 13−46.3%30.7% | 24r24+359%23.3% | 5.3r5.3−57.1%4.1% | 12r12+244%5.7% | 3.6—— | |
| Receivables | 5.3+10.5%17.9% | 4.8−14.9%17.1% | 5.6+20.9%18.8% | 4.7−11.3%16.4% | 5.3−48.6%15.4% | 10−5.1%24.2% | 11r11+25.3%10.4% | 8.6−50.1%6.7% | 17—8.0% | — | |
| Inventory | 3.3+13.2%11.1% | 2.9−10.0%10.3% | 3.2−3.2%10.8% | 3.3−35.2%11.7% | 5.1−18.8%15.1% | 6.3+49.3%15.0% | 4.2r4.2+37.9%4.1% | 3.1−74.7%2.4% | 12—5.7% | — | |
| Current assets | 16+4.5%53.6% | 15+2.4%54.2% | 15+18.3%49.7% | 13−19.9%44.2% | 16−50.0%46.0% | 31−65.0%74.2% | 90r90−21.8%86.3% | 115+107%88.9% | 55—25.7% | — | |
| Property, plant and equipment | 1.0+29.8%3.2% | 0.7−38.0%2.6% | 1.2−26.3%4.0% | 1.6−1.8%5.7% | 1.6+27.9%4.8% | 1.3+306%3.0% | 0.3r0.3+42.6%0.3% | 0.2−97.8%0.2% | 10—4.8% | — | |
| Goodwill | 3.4+8.8%11.4% | 3.1−2.4%11.1% | 3.2+6.8%10.6% | 3.0−0.4%10.5% | 3.0—8.8% | 0—0.0% | — | — | 47—22.1% | — | |
| Other intangible assets | 9.4+4.6%31.5% | 8.9−15.9%31.9% | 11−5.2%35.5% | 11−17.5%39.5% | 14+41.6%39.9% | 9.6+463%22.7% | 1.7r1.7−2.9%1.6% | 1.8−98.3%1.4% | 101—47.0% | — | |
| Non-current assets | 14+7.2%46.4% | 13−14.6%45.8% | 15−5.1%50.3% | 16−13.7%55.8% | 18+68.3%54.0% | 11−23.0%25.8% | 14r14−1.4%13.7% | 14−91.0%11.1% | 160—74.3% | — | |
| Total assets | 30+5.8%100% | 28−6.2%100% | 30+5.2%100% | 28−16.6%100% | 34−19.5%100% | 42−59.2%100% | 104r104−19.5%100% | 129−40.0%100% | 215—100% | — | |
| Accounts payable | 7.9+4.3%26.7% | 7.6+6.7%27.1% | 7.1+6.9%23.8% | 6.7−4.5%23.5% | 7.0−25.6%20.5% | 9.4−34.7%22.2% | 14r14+38.6%13.9% | 10−42.1%8.0% | 18—8.3% | — | |
| Current liabilities | 8.4+5.8%28.3% | 7.9−5.4%28.3% | 8.4−1.4%28.1% | 8.5−30.9%30.0% | 12+5.6%36.1% | 12−31.1%27.6% | 17r17−61.2%16.3% | 44−29.1%33.9% | 62—28.7% | — | |
| Long-term debt | — | — | — | — | — | — | — | — | 68—31.8% | — | |
| Lease liabilities (non-current) | 0.5+121%1.7% | 0.2−54.5%0.8% | 0.5−36.2%1.7% | 0.8−26.9%2.8% | 1.1+27.2%3.2% | 0.8—2.0% | — | — | — | — | |
| Non-current liabilities | 0.5+121%1.7% | 0.2−54.5%0.8% | 0.5−66.1%1.7% | 1.5−42.8%5.2% | 2.6−29.4%7.6% | 3.7+13.7%8.7% | 3.2r3.2−28.9%3.1% | 4.5−96.0%3.5% | 115—53.5% | — | |
| Total liabilities | 8.9+9.0%30.0% | 8.2−8.2%29.1% | 8.9−11.0%29.7% | 10.0−32.9%35.2% | 15−2.8%43.8% | 15−23.9%36.3% | 20r20−58.2%19.4% | 48−72.7%37.4% | 176—82.2% | — | |
| Retained earnings | −67—−225% | −66—−235% | −65—−217% | −66—−233% | −66—−193% | −63—−148% | −50r−50—−48.3% | −55—−42.3% | −98—−45.6% | — | |
| Shareholders' equity | — | — | — | — | — | — | — | 81+123%62.6% | 36—16.9% | — | |
| Minority interests | — | — | — | — | — | — | — | — | 2.1—1.0% | — | |
| Total equity | 21+4.4%70.0% | 20−5.3%70.9% | 21+14.1%70.3% | 18−3.8%64.8% | 19−28.9%56.2% | 27−67.8%63.7% | 84r84+3.6%80.6% | 81r81+111%62.6% | 38r38+758%17.8% | 4.5—— | |
| Total liabilities and equity | 30+5.8%100% | 28−6.2%100% | 30+5.2%100% | 28−16.6%100% | 34−19.5%100% | 42−59.2%100% | 104r104−19.5%100% | 129−40.0%100% | 215—100% | — | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 0.2−31.9%0.9% | 0.3+513%1.3% | 0.0−65.2%0.2% | 0.1−57.4%0.6% | 0.3−24.0%2.7% | 0.4−59.2%2.1% | 1.0r1.0+64.0%3.5% | 0.6r0.6−55.5%2.3% | 1.4−4.1%4.8% | 1.5—6.6% | |
| Cash from operating activities | 1.4−33.8%6.3% | 2.1+13.7%9.6% | 1.8−54.2%7.9% | 4.0—18.3% | −2.2—−19.3% | −15−2073%−72.6% | 0.7r0.7−96.6%2.5% | 22r22+242%80.8% | 6.4+4389%21.9% | 0.1—0.6% | |
| Intangible assets bought | −0.7—−3.4% | −0.3—−1.2% | −0.3—−1.3% | −0.4—−2.0% | — | −14—−67.7% | −1.3r−1.3—−4.4% | −0.1r−0.1—−0.5% | — | — | |
| Acquisitions, net of cash acquired | — | — | — | — | −7.2—−62.3% | — | — | — | −42—−142% | — | |
| Cash from investing activities | −0.7—−3.4% | −0.3—−1.2% | −0.3—−1.3% | −2.7—−12.4% | −7.2−121%−62.4% | 34+74.4%170% | 20r20−63.7%67.5% | 54r54—200% | −42—−144% | −0.2—−1.0% | |
| Debt issued | — | — | — | — | — | — | — | 0.2r0.2−51.3%0.6% | 0.3—1.1% | — | |
| Debt repaid | — | — | — | — | — | — | — | −63—−231% | −1.7—−5.7% | −0.7—−3.1% | |
| Shares bought back | — | — | 0—0.0% | — | −0.5—−4.5% | −4.1—−20.5% | −3.0r−3.0—−10.4% | — | — | — | |
| Cash from financing activities | −0.4—−1.7% | −0.3—−1.4% | −0.4—−1.5% | −0.3—−1.5% | −0.8—−6.6% | −30—−150% | −2.7r−2.7—−9.1% | −83r−83−286%−306% | 45+1327%152% | 3.1—14.1% | |
| Exchange-rate effect on cash | 0.6—2.5% | 0—0.0% | 0—0.0% | −0.0—−0.0% | −0.0—−0.0% | −0.6−149%−2.7% | 1.1—3.9% | — | — | — | |
| Change in cash | 0.8−45.6%3.8% | 1.5+30.0%7.0% | 1.2+18.9%5.0% | 1.0—4.5% | −10—−88.3% | −11−159%−55.4% | 19—64.9% | −7.0−181%−25.8% | 8.7+183%29.7% | 3.1—13.9% | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Medicure sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Retail and Mail Order Pharmacy$15 M70%+83%
- Marketing and Distribution of Commercial Products$6 M30%-24%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
How Medicure compares in Pharmaceutical
- Market cap$32 M · higher than 10% of 393
- Revenue$16 M · higher than 7% of 324
- Net margin-4.8% · higher than 23% of 313
- Revenue growth-0.4% · higher than 26% of 107
- Price / sales2.0× · lower than 57% of 219
- Price / book2.2× · lower than 49% of 207
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Medicure🇨🇦 | $32 M | — | -4.8% | -0.4% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Korea United Pharm Inc.$191 M
- Suheung Co., Ltd.$199 M
- JW Holdings Corporation$206 M
- Hester Biosciences Limited$214 M
- Venus Remedies Limited$215 M
- Windlas Biotech Limited$217 M
Sources and freshness
- Market cap:
- Oct 31, 2026
- Annual results:
- For year ending December-2024
- Balance sheet:
- As of December-2024
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Medicure? Verify and update this profile — free
Show Medicure's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.